Somewhat Positive Press Coverage Somewhat Unlikely to Impact Taro Pharmaceutical Industries (TARO) Stock Price
Headlines about Taro Pharmaceutical Industries (NYSE:TARO) have trended somewhat positive on Friday, according to Accern Sentiment. The research firm identifies negative and positive press coverage by monitoring more than twenty million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Taro Pharmaceutical Industries earned a daily sentiment score of 0.14 on Accern’s scale. Accern also assigned headlines about the company an impact score of 45.8646808710155 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the next several days.
Separately, BidaskClub lowered Taro Pharmaceutical Industries from a “buy” rating to a “hold” rating in a research note on Thursday, October 12th.
Shares of Taro Pharmaceutical Industries (NYSE:TARO) traded up $0.67 during trading hours on Friday, reaching $106.59. The company had a trading volume of 86,500 shares, compared to its average volume of 107,125. Taro Pharmaceutical Industries has a 52 week low of $94.00 and a 52 week high of $128.46. The stock has a market cap of $4,280.09, a P/E ratio of 13.14 and a beta of 0.62.
Taro Pharmaceutical Industries Company Profile
Taro Pharmaceutical Industries Ltd. (Taro) is a science-based pharmaceutical company. The Company operates principally through three entities: Taro Pharmaceutical Industries Ltd. (Taro Israel), and two of its subsidiaries, Taro Pharmaceuticals Inc (Taro Canada) and Taro U.SA The Company markets over 200 pharmaceutical products in over 25 countries.
Receive News & Stock Ratings for Taro Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Taro Pharmaceutical Industries and related stocks with our FREE daily email newsletter.